Easton Pharmaceutica Stock Debt To Equity
| EAPH Stock | USD 0.0001 0.00 0.00% |
Easton Pharmaceutica fundamentals help investors to digest information that contributes to Easton Pharmaceutica's financial success or failures. It also enables traders to predict the movement of Easton Stock. The fundamental analysis module provides a way to measure Easton Pharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Easton Pharmaceutica stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.32 | 0.31 |
Easton | Debt To Equity |
Easton Pharmaceutica Company Debt To Equity Analysis
Easton Pharmaceutica's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Easton Pharmaceutica Debt To Equity | 0.43 % |
Most of Easton Pharmaceutica's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Easton Pharmaceutica is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Easton Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Easton Pharmaceutica is extremely important. It helps to project a fair market value of Easton Stock properly, considering its historical fundamentals such as Debt To Equity. Since Easton Pharmaceutica's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Easton Pharmaceutica's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Easton Pharmaceutica's interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Easton Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Easton Pharmaceutica has a Debt To Equity of 0.426%. This is 99.2% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The debt to equity for all United States stocks is 99.13% higher than that of the company.
Easton Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Easton Pharmaceutica's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Easton Pharmaceutica could also be used in its relative valuation, which is a method of valuing Easton Pharmaceutica by comparing valuation metrics of similar companies.Easton Pharmaceutica is currently under evaluation in debt to equity category among its peers.
Easton Pharmaceutica Current Valuation Drivers
We derive many important indicators used in calculating different scores of Easton Pharmaceutica from analyzing Easton Pharmaceutica's financial statements. These drivers represent accounts that assess Easton Pharmaceutica's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Easton Pharmaceutica's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 28.0M | 10.4M | 1.3M | 807.0K | 726.3K | 690.0K | |
| Enterprise Value | 30.2M | 12.5M | 9.6M | 3.3M | 3.0M | 2.8M |
Easton Fundamentals
| Return On Equity | -0.0269 | ||||
| Return On Asset | -0.0083 | ||||
| Current Valuation | 2.14 M | ||||
| Shares Outstanding | 1.34 B | ||||
| Price To Earning | (22.00) X | ||||
| Price To Book | 0 X | ||||
| Price To Sales | 0.06 X | ||||
| Gross Profit | 201.4 K | ||||
| EBITDA | (188.54 K) | ||||
| Net Income | (188.54 K) | ||||
| Cash And Equivalents | 5.81 K | ||||
| Total Debt | 3.28 M | ||||
| Debt To Equity | 0.43 % | ||||
| Current Ratio | 0.69 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (188.54 K) | ||||
| Beta | 15.58 | ||||
| Market Capitalization | 134.49 K | ||||
| Total Asset | 10.19 M | ||||
| Retained Earnings | (39.82 M) | ||||
| Working Capital | (194.5 K) | ||||
| Current Asset | 297 K | ||||
| Current Liabilities | 137 K | ||||
| Net Asset | 10.19 M |
About Easton Pharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Easton Pharmaceutica's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Easton Pharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Easton Pharmaceutica based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Easton Pharmaceutica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Easton Pharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Easton Pharmaceutica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Easton Pharmaceutica Stock:Check out Easton Pharmaceutica Piotroski F Score and Easton Pharmaceutica Altman Z Score analysis. For more detail on how to invest in Easton Stock please use our How to Invest in Easton Pharmaceutica guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Easton Pharmaceutica. If investors know Easton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Easton Pharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.001 | Return On Assets (0.01) | Return On Equity (0.03) |
The market value of Easton Pharmaceutica is measured differently than its book value, which is the value of Easton that is recorded on the company's balance sheet. Investors also form their own opinion of Easton Pharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is Easton Pharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Easton Pharmaceutica's market value can be influenced by many factors that don't directly affect Easton Pharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Easton Pharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Easton Pharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Easton Pharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.